Abeona Therapeutics Inc. (ABEO)
After hours:
| Previous Close | 4.6600 |
| Open | 4.6200 |
| Bid | 4.4200 x 900 |
| Ask | 4.5700 x 2200 |
| Day's Range | 4.3900 - 4.9900 |
| 52 Week Range | 0.2700 - 34.0000 |
| Volume | |
| Avg. Volume | 166,546 |
| Market Cap | 26.36M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8080 |
| Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
- GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VIITAL™ reveal significant scope for pain reduction and EB-101 differentiation NEW YORK and CLEVELAND, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announ
- GlobeNewswire
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. In order to regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closin
- Zacks
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
